Korean J Hematol 2007; 42(4):
Published online December 30, 2007
https://doi.org/10.5045/kjh.2007.42.4.309
© The Korean Society of Hematology
고옥배, 김신, 이대호, 김상위. 허주령, 서철원
울산대학교 의과대학 서울아산병원내과, 임상병리과
Background:
The remission status prior to autologous stem cell transplantation (ASCT) influences the transplantation outcome in patients with relapsed or primary refractory diffuse large B cell lymphoma (DLBCL), a complete response (CR) generally being more favorable than a partial response (PR). This study investigated whether the addition of rituximab to the ESHAP chemotherapy regimen (R-ESHAP) could improve the CR rate in patients with relapsed or primary refractory DLBCL.
Methods: Retrospective analysis was performed with DLBCL registry data.
Results: Sixteen patients who had previously received one course of chemotherapy were administered R-ESHAP (median 3 cycles; range 1∼6). The overall response rate of 75% (CR=50%; PR=25%), was significantly better than that achieved with ESHAP alone in 13 historical controls (31%; P=0.027). The toxicity was tolerable, with two febrile neutropenia episodes in 51 treatment cycles. Seven of the 12 responders to R-ESHAP underwent ASCT with BEAM. After a median follow-up of 17 months, the median survival endpoints have not been reached.
Conclusion: R-ESHAP appears to induce high CR rates in relapsed or refractory DLBCL with acceptable toxicity. (Korean J Hematol 2007;42:309-316.)
Keywords Rituximab, ESHAP, Salvage chemotherapy, DLBCL
Korean J Hematol 2007; 42(4): 309-316
Published online December 30, 2007 https://doi.org/10.5045/kjh.2007.42.4.309
Copyright © The Korean Society of Hematology.
고옥배, 김신, 이대호, 김상위. 허주령, 서철원
울산대학교 의과대학 서울아산병원내과, 임상병리과
Ock Bae Ko, Shin Kim, Dae Ho Lee, Sang We Kim, Jooryung Huh, Cheolwon Suh
Departments of, Internal Medicine and, Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Background:
The remission status prior to autologous stem cell transplantation (ASCT) influences the transplantation outcome in patients with relapsed or primary refractory diffuse large B cell lymphoma (DLBCL), a complete response (CR) generally being more favorable than a partial response (PR). This study investigated whether the addition of rituximab to the ESHAP chemotherapy regimen (R-ESHAP) could improve the CR rate in patients with relapsed or primary refractory DLBCL.
Methods: Retrospective analysis was performed with DLBCL registry data.
Results: Sixteen patients who had previously received one course of chemotherapy were administered R-ESHAP (median 3 cycles; range 1∼6). The overall response rate of 75% (CR=50%; PR=25%), was significantly better than that achieved with ESHAP alone in 13 historical controls (31%; P=0.027). The toxicity was tolerable, with two febrile neutropenia episodes in 51 treatment cycles. Seven of the 12 responders to R-ESHAP underwent ASCT with BEAM. After a median follow-up of 17 months, the median survival endpoints have not been reached.
Conclusion: R-ESHAP appears to induce high CR rates in relapsed or refractory DLBCL with acceptable toxicity. (Korean J Hematol 2007;42:309-316.)
Keywords: Rituximab, ESHAP, Salvage chemotherapy, DLBCL
Naree Warnnissorn, Nonglak Kanitsap, Pimjai Niparuck, Paisarn Boonsakan, Prapasri Kulalert, Wasithep Limvorapitak, Lantarima Bhoopat, Supawee Saengboon, Chinnawut Suriyonplengsaeng, Pichika Chantrathammachart, Teeraya Puavilai and Suporn Chuncharunee
Blood Res 2024; 59():Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang
Blood Res 2022; 57(S1): S37-S43Woojung Jeon, Young Kwon Koh, Sunghan Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(1): 41-50